Day 5 Embryo Biopsy with SelectCCS Comprehensive Chromosomal Screening
Infertility experts agree that the shift toward single embryo transfer (SET) is quickly becoming the standard of care in IVF treatments, not only to improve overall health outcomes of mother and baby, but when coupled with advanced technologies of trophectoderm (outer layer of the blastocyst or 5 day embryo) biopsy and comprehensive chromosomal screening, SET can produce fertility rates on par with double embryo transfer (DET) and better than natural conception.
A major cause of an embryo’s failure to implant and miscarriage in IVF treatments results from non-chromosomally normal embryos, which occur more frequently after age 33. Historically, choosing embryos for transfer relied on a method of embryo selection using the physical appearance of the embryo. While still in use, this methodology lacks precision. Another technique that has fallen out of favor is the biopsy of the embryo at the early cleavage stage (day 2-3). This technique was shown to significantly compromise the ability of the embryo to implant.
Double Embryo Transfer: The Reasoning
IVF, as a treatment, is relatively new and has evolved very quickly since the first “test tube baby” was born in 1978. In that evolution, double embryo transfer (DET) became the standard of care in IVF cycles to up the chances of pregnancy. For many couples undergoing IVF treatments, the chance of twins is rarely viewed as a negative despite the potential increased health risks to mother and babies. As a result of the predominance of DET, the rate of twins resulting from fertility treatments is 20 times higher than spontaneous twins in the US.
How Day 5 (Trophectoderm) Biopsy and CCS Have Changed IVF
A recent comparative study by Reproductive Medicine Associates of New Jersey of women undergoing SET with comprehensive chromosomal screening versus women undergoing SET without screening resulted in higher pregnancy rates for women using CCS (55%) compared to those without CCS (41.8%). Additionally, the miscarriage rate was significantly less for the CCS-screened women (10.5% versus 24.8% in the unscreened women).
Another study determined that when compared to DET, SET CCS-screened embryos incurred similar pregnancy rates, resulted in lower miscarriage rates, eliminated multiple gestation (twins), and cut in half the rate of NICU admissions. Most significantly, the rate of singleton pregnancy for the CCS-SET group was 60.7% compared to only 33.7% for the DET group.
The movement towards SET in IVF as the new standard of care is extensively supported by the research and data produced from RMANJ. For women seeking to secure chromosomally stable embryos that haven’t been compromised in the biopsy process for implantation, the utilization of SelectCCS and day 5 biopsy shows the most promise and best clinically proven results.
Dr. Bobby Webster at FertilityAnswers/A Woman’s Center for Reproductive Medicine is an affiliate partner of the Reproductive Medicine Associates of New Jersey. He has been working with their laboratories in his provision of the SelectCCS screening to his patients. The addition of this SelectCCS screening to his patient’s IVF cycles will enable not only a safer day 5 screening of the embryos but also the security of a higher success rate on SET, resulting in fewer risks for mom and baby in pregnancy and delivery. Dr. Webster encourages anyone looking into IVF to also consider SelectCCS, and as one of the few Reproductive Endocrinologists selected to work with RMANJ, his credentials and care for patients make him one of the most highly recruited infertility specialists in the southern United States.
Dr. Webster also explains his new service offering, SelectCCS, in the informative video below.